The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $0.04 up 3.66% from its previous closing price of $0.04. In other words, the price has increased by $3.66 from its previous closing price. On the day, 28.07 million shares were traded. ADAP stock price reached its highest trading level at $0.046 during the session, while it also had its lowest trading level at $0.0403.
Ratios:
For a deeper understanding of Adaptimmune Therapeutics Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.52.
On June 26, 2025, Mizuho Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $0.50. On July 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $4.H.C. Wainwright initiated its Buy rating on July 30, 2024, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Wood Gavin sold 96,000 shares for $0.01 per share. The transaction valued at 950 led to the insider holds 0 shares of the business.
Gavin Wood bought 16,000 shares of ADAP for $942 on Sep 02 ’25. On Aug 28 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 207,000 shares for $0.01 each. As a result, the insider received 2,091 and left with 986,352 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 11264710 and an Enterprise Value of 90207152. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.17. Its current Enterprise Value per Revenue stands at 1.386 whereas that against EBITDA is -0.657.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.29, which has changed by -0.96018517 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.16, while it has fallen to a 52-week low of $0.04. The 50-Day Moving Average of the stock is -71.78%, while the 200-Day Moving Average is calculated to be -88.46%.
Shares Statistics:
For the past three months, ADAP has traded an average of 35.17M shares per day and 43836220 over the past ten days. A total of 265.05M shares are outstanding, with a floating share count of 255.38M. Insiders hold about 3.65% of the company’s shares, while institutions hold 27.58% stake in the company. Shares short for ADAP as of 1755216000 were 11073333 with a Short Ratio of 0.31, compared to 1752537600 on 3884668. Therefore, it implies a Short% of Shares Outstanding of 11073333 and a Short% of Float of 5.06.
Earnings Estimates
Current recommendations for the stock of the company come from 1.0 analysts. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.47 and -$0.47 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.5, with 1.0 analysts recommending between -$0.5 and -$0.5.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $12.31M this quarter.It ranges from a high estimate of $15.4M to a low estimate of $9.03M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $40.9MFor the next quarter, 4 analysts are estimating revenue of $15.23M. There is a high estimate of $20.1M for the next quarter, whereas the lowest estimate is $9.7M.
A total of 1 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $40.4M, while the lowest revenue estimate was $40.4M, resulting in an average revenue estimate of $40.4M. In the same quarter a year ago, actual revenue was $178.03MBased on 4 analysts’ estimates, the company’s revenue will be $64.09M in the next fiscal year. The high estimate is $85M and the low estimate is $41.4M.